Article

Variability in factor VIII concentrate measurement: results from SSC field collaborative studies.

Division of Haematology and Informatics Laboratory, National Institute for Biological Standards and Control, Potters Bar, UK.
Journal of Thrombosis and Haemostasis (Impact Factor: 6.08). 10/2003; 1(9):1927-34. DOI: 10.1046/j.1538-7836.2003.00342.x
Source: PubMed

ABSTRACT Seven 'field' collaborative studies on factor (F)VIII concentrate potency measurements were carried out, using local routine methodology, standards and calculation of results. Data from five of the 12 different concentrates studied are described in detail. These studies revealed that, for the intermediate-purity and the recombinant FVIII concentrates, one-stage potencies were significantly lower than chromogenic potencies, whilst for the two high-purity FVIII concentrates one-stage potencies were significantly greater than chromogenic potencies. On comparing predilution methods for the intermediate-purity concentrate, equivalent potencies were obtained using either buffer or FVIII-deficient plasma as prediluent. For the two high-purity and the recombinant concentrates, potencies obtained using buffer as prediluent were significantly greater and lower, respectively, than potencies obtained using FVIII-deficient plasma as prediluent. Interlaboratory variabilities were compared over all 12 concentrates studied and coefficients of variation (CVs) for one-stage assays were found to be much greater than for chromogenic assays. This was true for all concentrates except for the intermediate-purity concentrate and samples A and B from the first study, where the reverse was true. Furthermore, much better CVs were obtained when using FVIII-deficient plasma than when using buffer as prediluent, for all FVIII concentrates except for the intermediate-purity concentrate where the reverse was true, and sample B where CVs were equivalent. Overall, CVs were far worse than those obtained in controlled collaborative studies. Generally, however, CVs were better with chromogenic assays and predilution in FVIII-deficient plasma, as is recommended by the International Society on Thrombosis and Haemostasis/Scientific and Standardization Committee, particularly for higher purity and recombinant concentrates.

0 Bookmarks
 · 
65 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT:  Background: The basic prerequisite of factor (F) VIII clotting assay (FVIII:C) by one-stage method is that all clotting factors other than FVIII are present in constant concentration in each dilution of both standard reference and patient plasma curves. Indeed, the plasma content of each dilution should decrease as the dilution factor increases. Objectives and methods: To keep the plasma content exactly constant in each mixture, we performed all dilutions of both standard reference and patient plasma with FVIII-deficient plasma and with a fixed amount of buffer (method B). To show the discrepancies between this method and regular method A, using buffer to make dilutions, a comparative study was conducted on FVIII:C assay on samples at known FVIII concentration and in patient plasma. Imidazole or Owren's buffers and five different activated partial thromboplastin time reagents were employed, both in method A and B. Results: A discrepancy between FVIII:C assays obtained by methods A and B was observed, mainly when Pathrontin SL and Imidazole buffer were used. The assays derived from method B always fitted better with the expected, calculated, values of FVIII:C concentrations. Furthermore, FVIII:C was assayed in 60 patients: the outcome of method A was always higher than values of method B. The discrepancy between the two methods was higher at FVIII concentrations below 50 U dL−1 but nil at 100 U dL−1. The A slope was steeper than B slope and the difference was statistically significant starting from 1/10 dilution. Accordingly, FVIII:C of patients’ plasma obtained by method A was always higher than those obtained by method B, even two or three times for FVIII level ≤10 U dL−1 or 1.4–1.6 times for FVIII levels between 10 and 25 U dL−1. Conclusions: Only method B is able to give FVIII:C assays in agreement with the expected values. The dilution of reference standards and samples with FVIII-deficient plasma is crucial to accurately evaluate the postinfusion FVIII concentrations in pharmacokinetic studies or the trough level during prophylactic therapy and to investigate the discrepancy among different FVIII:C assays. In addition, the assessment of severity and classification of hemophilia should be reviewed.
    Journal of Thrombosis and Haemostasis 03/2006; 4(4):828 - 833. · 6.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The determination of factor VIII (FVIII) potency in FVIII concentrates can be performed using both manual and automated methods. This work aimed to validate the use of the chromogenic kit Coamatic(®) FVIII (Chromogenix) on the automated ACL(®) Elite PRO analyzer for evaluating the potency of FVIII in commercial preparations in pharmaceutical analytical laboratories. After setting the activation and reading times to 2 min and 3 min, respectively, the validation parameters, according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guideline Q2 (R1), were as follows: linearity, expressed by the adjusted model: log (Absorbance) = 1.848 + 0.777∙log (Concentration), with r(2) = 0.998; accuracy was verified (P-value = 0.6959); and the coefficient of variation for repeatability and intermediate precision was ≤6.5%. The Coamatic(®) FVIII kit method has been adapted to the ACL Elite PRO analyzer with improved performance compared with a manual microplate method.
    International journal of laboratory hematology 08/2012; · 1.30 Impact Factor
  • Source

Full-text

Download
0 Downloads